Clinical Trials Browser

Phase 3 × Completed × Nivolumab × Clear all

NCT02231749 2026-05-27

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase 3 Completed

1,096 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT04987203 2026-05-08

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Phase 3 Completed

Carcinoma, Renal Cell, Disease Progression

NCT05907122 2026-03-27

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Phase 3 Completed

Melanoma

NCT03143153 2026-02-17

CheckMate 648

Phase 3 Completed

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT04334759 2026-01-22

DREAM3R

Phase 3 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT02743494 2025-11-18

CheckMate 577

Phase 3 Completed

794 enrolled 13 charts 1 FDA

Advanced Cancer

NCT03469960 2025-11-18

DICIPLE

Phase 3 Completed

Non-Small Cell Lung Cancer Metastatic

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03906071 2025-10-21

SAPPHIRE

Phase 3 Completed

577 enrolled 22 charts

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT02872116 2025-08-07

CheckMate649

Phase 3 Completed

2,031 enrolled 19 charts 1 FDA

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04026412 2025-07-24

CheckMate73L

Phase 3 Completed

925 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT02667587 2025-06-18

CheckMate548

Phase 3 Completed

716 enrolled 15 charts

Brain Neoplasms

NCT04100018 2025-06-12

CheckMate 7DX

Phase 3 Completed

1,030 enrolled 25 charts

Prostatic Neoplasms

NCT01844505 2025-05-21

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Phase 3 Completed

945 enrolled 19 charts

Melanoma

NCT02388906 2025-04-24

CheckMate 238

Phase 3 Completed

906 enrolled 16 charts 1 FDA

Melanoma

NCT03063450 2025-04-10

CONFIRM

Phase 3 Completed

Other solid neoplasmThoracic

Mesothelioma

NCT02017717 2025-04-04

CheckMate 143

Phase 3 Completed

529 enrolled 28 charts

Glioblastoma

NCT03635983 2025-04-01

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Phase 3 Completed

783 enrolled 24 charts

Melanoma

NCT05297565 2025-02-27

CheckMate-6GE

Phase 3 Completed

14 enrolled 8 charts

Melanoma, Skin Neoplasms

NCT02576509 2025-02-17

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

Phase 3 Completed

743 enrolled 16 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04109066 2025-01-08

CheckMate 7FL

Phase 3 Completed

521 enrolled 17 charts

Breast Neoplasms, Neoplasms

NCT03138512 2024-12-18

CheckMate 914

Phase 3 Completed

1,641 enrolled 21 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT04340193 2024-11-26

CheckMate 74W

Phase 3 Completed

26 enrolled 15 charts

Gastrointestinal

Liver Neoplasms

NCT02613507 2024-11-19

CheckMate 078

Phase 3 Completed

504 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT03195491 2024-07-18

CheckMate870

Phase 3 Completed

400 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04209114 2024-06-27

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Phase 3 Completed

114 enrolled 17 charts

Urinary Bladder Neoplasms

NCT02899299 2024-05-21

CheckMate743

Phase 3 Completed

605 enrolled 17 charts 1 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT03117049 2024-05-06

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Phase 3 Completed

550 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT02267343 2024-05-03

Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer

Phase 3 Completed

Gastrointestinal

Stomach Neoplasms

NCT03006705 2024-05-03

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

Phase 3 Completed

Gastrointestinal

Stomach Neoplasms

NCT02864251 2023-09-28

CheckMate722

Phase 3 Completed

367 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT02741570 2023-09-21

CheckMate 651

Phase 3 Completed

947 enrolled 19 charts

Head and Neck Neoplasms

NCT02481830 2023-07-27

CheckMate331

Phase 3 Completed

569 enrolled 13 charts

Lung Neoplasms

NCT05802290 2023-04-06

NIVACTOR

Phase 3 Completed

Squamous Cell Carcinoma of Head and Neck

NCT02617589 2023-03-28

CheckMate 498

Phase 3 Completed

560 enrolled 14 charts

Brain Neoplasms

NCT02726581 2023-03-27

CheckMate 602

Phase 3 Completed

170 enrolled 16 charts

Multiple Myeloma

NCT02041533 2023-03-02

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Phase 3 Completed

541 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT03351361 2023-03-01

eNERGY

Phase 3 Completed

Advanced Non Small Cell Lung Cancer

NCT02713867 2023-02-14

CheckMate 384

Phase 3 Completed

363 enrolled 25 charts

Lung Neoplasms

NCT01673867 2023-02-08

CheckMate057

Phase 3 Completed

582 enrolled 18 charts

Non-Squamous Cell Non-small Cell Lung Cancer

NCT02538666 2023-01-05

CheckMate 451

Phase 3 Completed

907 enrolled 17 charts

Lung Neoplasms

NCT01642004 2022-12-28

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

Phase 3 Completed

272 enrolled 23 charts

Squamous Cell Non-small Cell Lung Cancer

NCT02066636 2022-10-27

CheckMate153

Phase 3 Completed

1,428 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT02105636 2022-10-05

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Phase 3 Completed

361 enrolled 14 charts

Squamous Cell Carcinoma of Head and Neck

NCT01668784 2022-08-09

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Phase 3 Completed

821 enrolled 18 charts

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT01721772 2022-07-12

CheckMate 066

Phase 3 Completed

418 enrolled 16 charts

Melanoma

NCT02569242 2022-07-06

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

Phase 3 Completed

419 enrolled 20 charts 1 FDA

Gastrointestinal

Esophageal Neoplasms